|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Rhythm Pharmaceuticals, Inc.
| | | Phone: | (857) 264-4280 | Fax: | (857) 264-4299 | Year Established: | 2008 | Ticker: | RYTM | Exchange: | NYSE | Main Contact: | Bart Henderson, MBA, President & Founder | | Other Contacts: | Lex H.T. Van der Ploeg, PhD, CSO Keith M. Gottesdiener, MD, CEO & Chairman Murray W. Stewart, M.D., CMO
| | Company Description | Rhythm Pharmaceuticals, is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases. Our lead product candidate, relamorelin, is a potent, best-in-class, Phase 2 ghrelin agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes, and other GI functional disorders.
On Oct. 28, 2016, Allergan and Rhythm Holding Company, which owns Motus Therapeutics, announced that Allergan has exercised its option to acquire Motus Therapeutics. | |
|
|
|
|
|